Jointly provided by Global Education Group and Physicians' Education Resource®, LLC (PER®)
Supported by an educational grant from Amgen Inc.
This crossfire is designed to educate clinicians regarding the latest clinical trial evidence for PCSK9 inhibitors (PCSK9i), emphasizing results from studies that evaluated coronary risk and cardiovascular outcomes. They will discuss the efficacy and safety data supporting these therapies, and the role of new therapies alongside traditional dyslipidemia treatment options. The activity will go beyond a simple overview of the trial results to guide clinicians in how to interpret the clinical implications of the findings to improve the management of CV risk in their patients.
This educational activity is directed toward lipidologists, cardiologists, nurse practitioners, nurses, physician assistants, researchers, and other healthcare professionals interested in the treatment of hypercholesterolemia.
At the conclusion of this activity, participants should be better able to:
Determine optimal LDL-C target goals in high-risk individuals in light of current consensus recommendations
Review the latest clinical trial data for the novel LDL-C lowering agents, PCSK9 inhibitors, and their potential application to address ASCVD risk in clinical practice
Discuss new data and how it will benefit individualized treatment plans to improve outcomes and lower the risk of cardiovascular events for patients with dyslipidemia
Disclosure of Conflicts of Interest Policy
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Elliot A. Brinton, MD, FAHA, FNLA President, Utah Lipid Center Salt Lake City, UT
Dr. Brinton discloses the following: Consultant: Amgen, Kowa, Regeneron, and Sanofi Speakers Bureau: Amgen, Kowa, Regeneron, and Sanofi
Michael Davidson, MD, FACC, FNLA Professor at the University of Chicago Pritzker School of Medicine Chicago, IL
Dr. Davidson discloses the following: Consultant: Amgen, AstraZeneca, Merck, Novo Nordisk, Regeneron, and Sanofi US Speakers Bureau: Amgen, Novo Nordisk, Regeneron, and Sanofi US
Peter Salgo, MD Professor of Medicine and Anesthesiology Columbia University College of Physicians and Surgeons New York, NY
Dr. Salgo has no relevant financial relationships with commercial interests to disclose.
James Underberg, MD President of the National Lipid Association Clinical Assistant Professor of Medicine at the New York University School of Medicine New York, NY
Dr. Underberg discloses the following: Grant Research Support: Aegerion and Pfizer Consultant: Amarin and Amgen Speakers Bureau: Alexioin, Amarin, Amgen, Kowa, Regeneron, Sanofi, and True Health Diagnostics
Accredited Provider Disclosure
Global Education Group Planning Staff—Lindsay Borvansky; Andrea Funk; and Liddy Knight have no relevant financial relationships with commercial interests to disclose.
Publishing Staff Disclosures
Physicians' Education Resource®, LLC (PER®) Planning Staff—David Heckard; Maryjo Dixon, RPh; Neelam Davis, PharmD; and Kathleen Bowen have no relevant financial relationships with commercial interests to disclose.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Physicians’ Education Resource®, LLC (PER®). Global is accredited by the ACCME to provide continuing medical education for physicians.
Global Education Group designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.